4.7 Article

The Cardiovascular Risk of White-Coat Hypertension

Journal

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
Volume 68, Issue 19, Pages 2033-2043

Publisher

ELSEVIER SCIENCE INC
DOI: 10.1016/j.jacc.2016.08.035

Keywords

ambulatory blood pressure monitoring; cardiovascular disease; epidemiology; white-coat effect

Funding

  1. European Union [IC15-CT98-0329-EPOGH, LSHM-CT-2006-037093 InGenious HyperCare, HEALTH-F4-2007-201550 HyperGenes, HEALTH-F7-2011-278249 EU-MASCARA, HEALTH-F7-305507 HOMAGE, LSHM-CT-2006-037093, HEALTH-F4-2007-201550]
  2. European Union (European Research Council Advanced Research Grant) [294713 EPLORE]
  3. Fonds voor Wetenschappelijk Onderzoek Vlaanderen, Ministry of the Flemish Community, Brussels, Belgium [G.0734.09, G.0881.13, G.0880.13N]
  4. Danish Heart Foundation [01-2-9-9A-22914]
  5. Lundbeck Fonden [R32-A2740]
  6. Ministry of Education, Culture, Sports, Science and Technology, Japan [22590767, 22790556, 23249036, 23390171, 23790242]
  7. Health Labour Sciences Research Grant from the Ministry of Health, Labour and Welfare, Japan [H23-Junkankitou[Seishuu]-Ippan-005]
  8. Japan Arteriosclerosis Prevention Fund
  9. Central Miso Research Institute, Tokyo, Japan
  10. National Natural Science Foundation of China, Beijing, China [30871360, 30871081]
  11. Shanghai Commission of Science and Technology [07JC14047, 06QA14043]
  12. Shanghai Commission of Education [07ZZ32]
  13. Comision Sectorial de Investigacion Cientifica de la Universidad de la Republica (Grant I+D GEFA-HT-UY)
  14. Agencia Nacional de Innovacion e Investigacion
  15. Charles University Research Fund [P36]

Ask authors/readers for more resources

BACKGROUND The role of white-coat hypertension (WCH) and the white-coat-effect (WCE) in development of cardiovascular disease (CVD) risk remains poorly understood. OBJECTIVES Using data from the population-based, 11-cohort IDACO (International Database on Ambulatory Blood Pressure Monitoring in Relation to Cardiovascular Outcomes), this study compared daytime ambulatory blood pressure monitoring with conventional blood pressure measurements in 653 untreated subjects with WCH and 653 normotensive control subjects. METHODS European Society Hypertension guidelines were used as a 5-stage risk score. Low risk was defined as 0 to 2 risk factors, and high risk was defined as >= 3 to 5 risk factors, diabetes, and/or history of prior CVD events. Age-and cohort-matching was done between 653 untreated subjects with WCH and 653 normotensive control subjects. RESULTS In a stepwise linear regression model, systolic WCE increased by 3.8 mm Hg (95% confidence interval [CI]: 3.1 to 4.6 mm Hg) per 10-year increase in age, and was similar in low-and high-risk subjects with or without prior CVD events. Over a median 10.6-year follow-up, incidence of new CVD events was higher in 159 high-risk subjects with WCH compared with 159 cohort-and age-matched high-risk normotensive subjects (adjusted hazard ratio [HR]: 2.06; 95% CI: 1.10 to 3.84; p = 0.023). The HR was not significant for 494 participants with low-risk WCH and age-matched low-risk normotensive subjects. Subgroup analysis by age showed that an association between WCH and incident CVD events is limited to older (age >= 60 years) high-risk WCH subjects; the adjusted HR was 2.19 (95% CI: 1.09 to 4.37; p = 0.027) in the older high-risk group and 0.88 (95% CI: 0.51 to 1.53; p = 0.66) in the older low-risk group (p for interaction = 0.044). CONCLUSIONS WCE size is related to aging, not to CVD risk. CVD risk in most persons with WCH is comparable to age-and risk-adjusted normotensive control subjects. (C) 2016 by the American College of Cardiology Foundation.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available